Safety of low dose inpatient zoledronic acid in acute hip fracture patients with advanced chronic kidney disease.

IF 6.5 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Xiaoxu Sun, Benjamin Z Leder, Thuan V Ly, Esteban Franco-Garcia, Marcy B Bolster, WuQiang Fan
{"title":"Safety of low dose inpatient zoledronic acid in acute hip fracture patients with advanced chronic kidney disease.","authors":"Xiaoxu Sun, Benjamin Z Leder, Thuan V Ly, Esteban Franco-Garcia, Marcy B Bolster, WuQiang Fan","doi":"10.1093/jbmr/zjaf195","DOIUrl":null,"url":null,"abstract":"<p><p>Zoledronic acid (ZA), cleared renally, carries a higher nephrotoxicity risk at doses ≥4 mg, especially in patients with CKD. While 5 mg is standard for osteoporosis, ZA increases BMD at doses as low as 0.25 mg every 3 mo. Inpatient ZA (IP-ZA) in hip fracture patients reduces mortality and re-fracture risk, but its safety in those with advanced CKD (creatinine clearance rate (CrCl) < 35 mL/min) is unclear. We analyzed real-world data from a large academic healthcare system to assess the safety of reduced-dose IP-ZA (≤3 mg) in hip fracture patients with advanced CKD, compared to propensity-matched controls receiving no anti-osteoporosis medication during index hip fracture hospitalization. The study included 328 IP-ZA patients and 2308 controls, with a primary cohort of 46 IP-ZA patients and 98 matched untreated controls, predominantly female (77.8%), White (92.4%), with a mean age of 89.9 yr and CrCl of 31.1 ± 0.6 mL/min. The IP-ZA group received an average dose of 2.7 ± 0.1 mg (1 patient at 1 mg, 11 at 2 mg, 34 at 3 mg) on postoperative day 2.9 ± 0.3. All patients received standing acetaminophen, calcium (650-1000 mg/d), and vitamin D (1000-2500 IU/d) post-surgery. We monitored daily maximum body temperature, serum creatinine, and serum calcium for 5 d, starting the day before IP-ZA administration (or postoperative day 2 for controls). Inpatient-ZA did not affect temperature, with new-onset fever (≥38.0 °C, days 2-4) in 1 IP-ZA patient and 2 controls. Serum creatinine level remained stable. Serum calcium level in the IP-ZA group decreased from 8.8 ± 0.1 to 8.2 ± 0.2 mg/dL by day 5, unchanged in controls; no IP-ZA patient had serum calcium level <7.5 mg/dL. Hospital length-of-stay (6.2 ± 0.4 vs 6.5 ± 0.4 d, p = .41) and 30-d readmission rates were similar. This study suggests that reduced-dose IP-ZA is likely safe for patients with hip fracture and advanced CKD who are otherwise at high risk for being untreated.</p>","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":" ","pages":"710-716"},"PeriodicalIF":6.5000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Mineral Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jbmr/zjaf195","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Zoledronic acid (ZA), cleared renally, carries a higher nephrotoxicity risk at doses ≥4 mg, especially in patients with CKD. While 5 mg is standard for osteoporosis, ZA increases BMD at doses as low as 0.25 mg every 3 mo. Inpatient ZA (IP-ZA) in hip fracture patients reduces mortality and re-fracture risk, but its safety in those with advanced CKD (creatinine clearance rate (CrCl) < 35 mL/min) is unclear. We analyzed real-world data from a large academic healthcare system to assess the safety of reduced-dose IP-ZA (≤3 mg) in hip fracture patients with advanced CKD, compared to propensity-matched controls receiving no anti-osteoporosis medication during index hip fracture hospitalization. The study included 328 IP-ZA patients and 2308 controls, with a primary cohort of 46 IP-ZA patients and 98 matched untreated controls, predominantly female (77.8%), White (92.4%), with a mean age of 89.9 yr and CrCl of 31.1 ± 0.6 mL/min. The IP-ZA group received an average dose of 2.7 ± 0.1 mg (1 patient at 1 mg, 11 at 2 mg, 34 at 3 mg) on postoperative day 2.9 ± 0.3. All patients received standing acetaminophen, calcium (650-1000 mg/d), and vitamin D (1000-2500 IU/d) post-surgery. We monitored daily maximum body temperature, serum creatinine, and serum calcium for 5 d, starting the day before IP-ZA administration (or postoperative day 2 for controls). Inpatient-ZA did not affect temperature, with new-onset fever (≥38.0 °C, days 2-4) in 1 IP-ZA patient and 2 controls. Serum creatinine level remained stable. Serum calcium level in the IP-ZA group decreased from 8.8 ± 0.1 to 8.2 ± 0.2 mg/dL by day 5, unchanged in controls; no IP-ZA patient had serum calcium level <7.5 mg/dL. Hospital length-of-stay (6.2 ± 0.4 vs 6.5 ± 0.4 d, p = .41) and 30-d readmission rates were similar. This study suggests that reduced-dose IP-ZA is likely safe for patients with hip fracture and advanced CKD who are otherwise at high risk for being untreated.

低剂量唑来膦酸治疗急性髋部骨折合并晚期慢性肾病患者的安全性
唑来膦酸(ZA),经肾脏清除,在剂量≥4mg时具有更高的肾毒性风险,特别是对于慢性肾病(CKD)患者。虽然骨质疏松症的标准剂量为5mg,但每3个月服用低至0.25 mg的ZA可增加骨密度。髋部骨折患者的住院ZA (IP-ZA)可降低死亡率和再骨折风险,但其在晚期CKD患者中的安全性[肌酐清除率(CrCl)]。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Bone and Mineral Research
Journal of Bone and Mineral Research 医学-内分泌学与代谢
CiteScore
11.30
自引率
6.50%
发文量
257
审稿时长
2 months
期刊介绍: The Journal of Bone and Mineral Research (JBMR) publishes highly impactful original manuscripts, reviews, and special articles on basic, translational and clinical investigations relevant to the musculoskeletal system and mineral metabolism. Specifically, the journal is interested in original research on the biology and physiology of skeletal tissues, interdisciplinary research spanning the musculoskeletal and other systems, including but not limited to immunology, hematology, energy metabolism, cancer biology, and neurology, and systems biology topics using large scale “-omics” approaches. The journal welcomes clinical research on the pathophysiology, treatment and prevention of osteoporosis and fractures, as well as sarcopenia, disorders of bone and mineral metabolism, and rare or genetically determined bone diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书